If your gastroenterologist has prescribed Skyrizi for Crohn's disease and you carry an Aetna plan, the short answer is that Aetna does cover risankizumab for moderately to severely active Crohn's disease, but coverage runs through a precertification process and depends on how your specific plan is built. Skyrizi, known generically as risankizumab-rzaa, is an interleukin-23 antagonist that selectively binds the p19 subunit of IL-23, and it carries an FDA-approved Crohn's indication. Because Aetna is a CVS Health company, your Skyrizi claim may touch both the medical benefit and the pharmacy benefit managed through CVS Caremark, which makes understanding the mechanics worthwhile before your first dose.
What Aetna's Clinical Policy Bulletin Says
Aetna documents how it evaluates risankizumab in Clinical Policy Bulletin 1009, the published medical policy for Skyrizi. For moderately to severely active Crohn's disease, that bulletin treats risankizumab as medically necessary and, notably, does not require documented failure of a preferred anti-TNF biologic before approval, which is a meaningful contrast with how some payers gate IL-23 inhibitors. The CPB does set clear conditions. It requires that the medication be prescribed by or in consultation with a gastroenterologist, and it requires precertification for intravenous risankizumab in applicable plan designs. Reading the actual bulletin matters, because the document Aetna applies to your request is the same one your prescriber's office uses to assemble the prior authorization packet.
Why Skyrizi Needs Prior Authorization
Skyrizi sits squarely in the category of medications that payers gate before dispensing. CVS Caremark, the pharmacy benefit manager behind most Aetna plans, requires prior authorization for drugs that are expensive, limited to a specific patient population, or subject to off-label use, and a high-cost specialty biologic like risankizumab meets that description. Prior authorization is the step where Aetna or Caremark confirms that your situation matches the coverage criteria in the policy before agreeing to pay. The practical implication is that your gastroenterologist's office, not you, submits the clinical information, and the strength of that submission largely determines whether the request clears on the first pass or triggers a back-and-forth.
The Two-Benefit Split That Trips People Up
Skyrizi for Crohn's uses a split regimen that can cross two different parts of your coverage. The label calls for 600 mg by intravenous infusion at weeks 0, 4, and 8, followed by 180 mg or 360 mg by subcutaneous injection at week 12 and every 8 weeks thereafter. The intravenous induction doses are often billed under the medical benefit and may run through Aetna's precertification line, while the subcutaneous maintenance pens are typically filled through CVS Specialty under the pharmacy benefit. That split is why a member can have induction approved and then hit a separate review for maintenance. Knowing which benefit each phase falls under helps you anticipate where a delay might occur and whom to call.
Building a Strong Medical-Necessity Case
A clean prior authorization rests on documentation that mirrors the evidence base Aetna relies on. Risankizumab earned its Crohn's approval on the phase 3 ADVANCE and MOTIVATE induction trials, where intravenous risankizumab produced significantly higher clinical remission and endoscopic response at week 12 than placebo, and on the FORTIFY maintenance trial, where subcutaneous dosing every 8 weeks maintained remission through week 52. To match the CPB criteria, your prescriber should document gastroenterologist involvement, objective disease activity such as endoscopic findings or biomarkers, and a current negative tuberculosis test, which the bulletin expects before starting a biologic. The more your file resembles the population studied in those trials, the smoother the review tends to go.
Reading Your Own Plan Before You Assume
Clinical Policy Bulletin 1009 describes Aetna's default medical position, but your individual plan can layer additional rules on top, including formulary tier placement and step therapy applied through the pharmacy benefit. Two Aetna members can therefore get different answers for the same drug. The reliable move is to pull your own plan's formulary and benefit documents, or call the member services number on your card, and ask specifically whether Skyrizi requires step therapy under your pharmacy benefit and which specialty pharmacy will fill it. Confirming these details before induction begins prevents the common scenario where infusions start and a maintenance fill stalls weeks later over a rule nobody flagged.
If Aetna Denies the Request
A denial is not the end of the road, and the appeal window is generous. Aetna's complaints, grievances, and appeals process lets members challenge an adverse coverage decision, and your denial letter will state the reason and the deadline. A persuasive appeal pairs a physician letter of medical necessity with the specific clinical evidence the denial overlooked, often the trial data and the objective measures of disease activity already in your chart. When delaying treatment could worsen your condition, ask explicitly for an expedited review. If an internal appeal is upheld against you, you generally retain the right to an independent external review, which moves the decision outside Aetna entirely.
The Bottom Line on Aetna and Skyrizi
Aetna does cover Skyrizi for moderately to severely active Crohn's disease, and its published policy is comparatively accessible because Clinical Policy Bulletin 1009 does not force a preferred anti-TNF failure first. The friction tends to live in the mechanics: the gastroenterologist requirement, the precertification step, the split between medical and pharmacy benefits, and any step therapy your individual plan adds. None of these guarantees a particular tier, copay, or outcome, and the only authoritative source for your exact terms is your own plan documents. Approach the process by reading the bulletin, confirming your benefit details, documenting medical necessity thoroughly, and treating a denial as a step you can appeal rather than a final verdict.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.